But a new research that was released on Monday suggested that there is a modest association between the overall absorption of radioactive iodine by various organs and the increased risk of
solid cancer deaths.
TUESDAY, July 2, 2019 (HealthDay News) -- For patients with hyperthyroidism treated with radioactive iodine (RAI), greater organ-absorbed doses seem to be positively associated with increased risk of death from
solid cancer, according to a study published online July 1 in JAMA Internal Medicine.
The study couldn't prove cause-and-effect, but "we identified a clear dose-response relationship between this widely used treatment and long-term risk of death from
solid cancer, including breast cancer, in the largest cohort study to date of patients treated for hyperthyroidism," said lead author Cari Kitahara.
Lead researcher professor Attila Lorincz, PhD, who helped develop the world's first test for HPV, says, "We're not only astounded by how well this test detects cervical cancer, but it is the first time that anyone has proven the key role of epigenetics in the development of a major
solid cancer using data from patients in the clinic."
"My personal feeling is where we are with CAR-T cell treatment in
solid cancer is kind of where we were with leukaemia and lymphoma about seven or eight years ago."
The exciting potential of cancer immunotherapies means that utilising the pre-existing immunity of cancer patients can result in complete remission of advanced
solid cancer in patients.
This upcoming phase I study of ATOR-1015 is a first-in-human dose escalation study in patients with advanced
solid cancer. The study will be conducted at five sites in Sweden and Denmark.
Further, the author applied the general formula to the data on dose versus cancer mortality risk published by the United Nations Scientific Committee on the effects of atomic radiation and other investigators to construct general formulas expressing a relationship between dose and
solid cancer or leukemia mortality probability after exposure to acute low-dose ionizing radiation in humans on earth.
"Unlike
solid cancer tumours, blood cancer cannot be surgically cut out, and consequently blood cancer patients have a very different experience to other people with cancer.
The preventive screening test that will cost between Dh2,500 and Dh4,500 could assess
solid cancer risk, except that of the brain.
Most
solid cancer tumours that have outgrown their blood supply, and are therefore deprived of oxygen, are difficult to treat, and the cells within are capable of spreading rapidly and doing the most damage.
CLS develops and markets heat-induced cancer immunotherapy for gentle and effective treatment of most types of
solid cancer tumors.